Behçet disease, familial Mediterranean fever and MEFV variations: More than just an association.
Autoinflammation
Behçet disease
Familial Mediterranean fever
MEFV gene variants
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
13
04
2023
revised:
20
04
2023
accepted:
21
04
2023
medline:
24
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
Behçet disease (BD) and familial Mediterranean fever (FMF) are two inflammatory disorders that share many features including historical background, ethnical distribution and inflammatory characteristics. Several studies suggested that BD and FMF might occur in the same individual more commonly than expected. Additionally, the pathogenic MEFV gene variants, especially p.Met694Val, activating the inflammasome complex have been shown to increase the risk for BD in regions where both FMF and BD are prevalent. Whether these variants are associated with certain disease subtypes and whether they may help in the planning of treatment need to be explored. This review provides a recent overview of the plausible association between FMF and BD and the role of MEFV variants in the pathogenesis of BD.
Identifiants
pubmed: 37216220
pii: S1521-6616(23)00129-8
doi: 10.1016/j.clim.2023.109630
pii:
doi:
Substances chimiques
Pyrin
0
MEFV protein, human
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109630Informations de copyright
Copyright © 2023. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Emire Seyahi has received honoraria, consulting, or speaker fees from Novartis, Pfizer, and AbbVie. Serdal Ugurlu has received honoraria, consulting, or speaker fees from Novartis, Pfizer, Lilly and Celltrion. Shirkhan Amikishiyev has nothing to declare, Ahmet Gul has received honoraria, consulting, or speaker fees from Novartis, Pfizer, Lilly, AbbVie, R-Pharm.